Cargando…

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro

Locked nucleic acid is a prominent nucleic acid analog with unprecedented target binding affinity to cDNA and RNA oligonucleotides and shows remarkable stability against nuclease degradation. Incorporation of locked nucleic acid nucleotides into an antisense oligonucleotide (AO) sequence can reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Bao T., Adams, Abbie M., Fletcher, Susan, Wilton, Stephen D., Veedu, Rakesh N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633351/
https://www.ncbi.nlm.nih.gov/pubmed/29246294
http://dx.doi.org/10.1016/j.omtn.2017.09.002
_version_ 1783269877321039872
author Le, Bao T.
Adams, Abbie M.
Fletcher, Susan
Wilton, Stephen D.
Veedu, Rakesh N.
author_facet Le, Bao T.
Adams, Abbie M.
Fletcher, Susan
Wilton, Stephen D.
Veedu, Rakesh N.
author_sort Le, Bao T.
collection PubMed
description Locked nucleic acid is a prominent nucleic acid analog with unprecedented target binding affinity to cDNA and RNA oligonucleotides and shows remarkable stability against nuclease degradation. Incorporation of locked nucleic acid nucleotides into an antisense oligonucleotide (AO) sequence can reduce the length required without compromising the efficacy. In this study, we synthesized a series of systematically truncated locked nucleic acid-modified 2′-O-methyl AOs on a phosphorothioate (PS) backbone that were designed to induce skipping exon 23 from the dystrophin transcript in H-2K(b)-tsA58 mdx mouse myotubes in vitro. The results clearly demonstrated that shorter AOs (16- to 14-mer) containing locked nucleic acid nucleotides efficiently induced dystrophin exon 23 skipping compared with the corresponding 2′-O-methyl AOs. Our remarkable findings contribute significantly to the existing knowledge about the designing of short LNA-modified oligonucleotides for exon-skipping applications, which will help reduce the cost of exon-skipping AOs and potential toxicities, particularly the 2′-OMe-based oligos, by further reducing the length of AOs.
format Online
Article
Text
id pubmed-5633351
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-56333512017-10-13 Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro Le, Bao T. Adams, Abbie M. Fletcher, Susan Wilton, Stephen D. Veedu, Rakesh N. Mol Ther Nucleic Acids Article Locked nucleic acid is a prominent nucleic acid analog with unprecedented target binding affinity to cDNA and RNA oligonucleotides and shows remarkable stability against nuclease degradation. Incorporation of locked nucleic acid nucleotides into an antisense oligonucleotide (AO) sequence can reduce the length required without compromising the efficacy. In this study, we synthesized a series of systematically truncated locked nucleic acid-modified 2′-O-methyl AOs on a phosphorothioate (PS) backbone that were designed to induce skipping exon 23 from the dystrophin transcript in H-2K(b)-tsA58 mdx mouse myotubes in vitro. The results clearly demonstrated that shorter AOs (16- to 14-mer) containing locked nucleic acid nucleotides efficiently induced dystrophin exon 23 skipping compared with the corresponding 2′-O-methyl AOs. Our remarkable findings contribute significantly to the existing knowledge about the designing of short LNA-modified oligonucleotides for exon-skipping applications, which will help reduce the cost of exon-skipping AOs and potential toxicities, particularly the 2′-OMe-based oligos, by further reducing the length of AOs. American Society of Gene & Cell Therapy 2017-09-12 /pmc/articles/PMC5633351/ /pubmed/29246294 http://dx.doi.org/10.1016/j.omtn.2017.09.002 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Le, Bao T.
Adams, Abbie M.
Fletcher, Susan
Wilton, Stephen D.
Veedu, Rakesh N.
Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title_full Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title_fullStr Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title_full_unstemmed Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title_short Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
title_sort rational design of short locked nucleic acid-modified 2′-o-methyl antisense oligonucleotides for efficient exon-skipping in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633351/
https://www.ncbi.nlm.nih.gov/pubmed/29246294
http://dx.doi.org/10.1016/j.omtn.2017.09.002
work_keys_str_mv AT lebaot rationaldesignofshortlockednucleicacidmodified2omethylantisenseoligonucleotidesforefficientexonskippinginvitro
AT adamsabbiem rationaldesignofshortlockednucleicacidmodified2omethylantisenseoligonucleotidesforefficientexonskippinginvitro
AT fletchersusan rationaldesignofshortlockednucleicacidmodified2omethylantisenseoligonucleotidesforefficientexonskippinginvitro
AT wiltonstephend rationaldesignofshortlockednucleicacidmodified2omethylantisenseoligonucleotidesforefficientexonskippinginvitro
AT veedurakeshn rationaldesignofshortlockednucleicacidmodified2omethylantisenseoligonucleotidesforefficientexonskippinginvitro